Drugs / EgyVax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05218070 | Feb → Oct 2022 | COVID-19 | Eva Pharma | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-02-28 | Eva Pharma | EVA Pharma signs agreement with Egyptian ministries of Scientific Research and Agriculture to produce local COVID-19 vaccine “Egyvax” evapharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EgyVax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05218070 ↗ |
| Modality | Vaccine | “EgyVax Inactivated SARS-CoV-2 vaccine candidate” NCT05218070 ↗ |
| Route | Intramuscular | “via intramuscular (IM) injection in the upper arm approximately 14 days apart” NCT05218070 ↗ |